Hedge funds are buying these two big tech stocks while selling two rivals
NEW YORK - Aetna, a CVS Health company (NYSE:CVS), announced Tuesday the launch of a generative AI-powered conversational assistant embedded throughout its digital platforms to help members navigate their health benefits more easily. CVS Health shares have surged 82% year-to-date and appear undervalued according to InvestingPro Fair Value estimates, reflecting investor confidence in the company’s digital transformation initiatives.
Unlike traditional chatbot solutions confined to separate windows, Aetna’s approach integrates the AI assistant directly into its website and mobile app experiences. The system is designed to understand plain language queries without requiring members to use technical healthcare terminology.
"At Aetna, we are constantly innovating, leveraging tools like generative AI, to provide a personalized experience and help our members navigate healthcare in a new way," said Nathan Frank, SVP and Aetna’s Chief Digital and Technology officer, according to the company’s press release.
The AI assistant features dynamically generated user interface components that provide visual aids such as maps, charts, and financial breakdowns tailored to specific queries. Members can ask practical questions about finding providers, understanding coverage requirements, or analyzing healthcare costs.
Initially launched to a beta population in October, Aetna plans to expand access throughout 2025 and the first half of 2026. Future enhancements will include proactive AI insights, multimodal interaction supporting voice and text, and integration with Aetna’s Care Paths feature, which helps members navigate specific medical conditions.
The development represents part of Aetna’s broader strategy to transition from traditional transactional experiences to a more consumer-focused health experience, according to the company statement.
Aetna serves approximately 37 million people with its range of health insurance products and related services. Its parent company, CVS Health, operates about 9,000 retail pharmacy locations and more than 1,000 walk-in and primary care medical clinics across the United States.
In other recent news, CVS Health reported its Q3 2025 earnings, surpassing analyst expectations with an adjusted earnings per share of $1.60, compared to the forecasted $1.37. The company also exceeded revenue projections, posting $103 billion against an expected $98.88 billion. This performance highlights CVS Health’s strategic initiatives and operational efficiencies. Additionally, Evercore ISI raised its price target for CVS Health to $95 from $85, maintaining an Outperform rating. The firm anticipates mid-teens earnings per share growth for fiscal year 2026, excluding a prior year development benefit. Meanwhile, Eli Lilly announced it would remove CVS Health as its employee drug benefit provider. This decision follows CVS’s choice to stop covering Lilly’s weight-loss medication in favor of a competing drug from Novo Nordisk. Starting January 1, Eli Lilly employees will be automatically enrolled in pharmacy benefit coverage through Rightway.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.